Christine S. Walsh, MD

Director, Gynecologic Oncology Fellowship Program

Associate Professor, Obstetrics and Gynecology

Samuel Oschin Comprehensive Cancer Institute
8700 Beverly Blvd.
North Tower, Lower Level
Los Angeles, CA 90048





Christine S. Walsh, MD

Director, Gynecologic Oncology Fellowship Program

Associate Professor, Obstetrics and Gynecology

  • OB/GYN-Oncology

BRCA (Mutation, Positive, Carrier)

Cervical Tumors

Fallopian Tube Cancers

Gestational Trophoblast Disease

Ovarian Cancers

Pelvic Mass

Postmenopausal Bleeding

Uterine Cancers

Vaginal Cancers

Vulvar Cancers

The research of Christine S. Walsh, MD currently focuses on clinical trials. She is currently principal investigator for a single-institution investigator initiated clinical trial studying the efficacy of an immune checkpoint inhibitor in ovarian cancer treatment. Title: A Phase II Study of Pembrolizumab in Combination with Gemcitabine and Cisplatin in Patients with Recurrent Platinum-Resistant Ovarian Cancer. Summary: IIT2015-13-Walsh-PemCiGem: Phase 2 Study of Pembrolizumab with SOC Treatment in Recurrent Platinum-resistant Ovarian Cancer.

  • Undergraduate: Stanford University, 1994
  • Medical School: Columbia University College of Physicians and Surgeons, 1998
  • Residency: Brigham and Women's Hospital, 2002
  • Fellowship: UCLA/Cedars-Sinai, 2005
  • The American Association of Obstetricians and Gynecologists Foundation, ABOG/AAOGF Bridge Funding Award Recipient, 2014
  • APGO Faculty Teaching Award, 2011
  • Marsha Rivkin Center for Ovarian Cancer Research, Pilot Award Recipient, 2011
  • Career Development Award, Department of Defense Ovarian Cancer Research Program, 2008
  • Career Development Award, American Society of Clinical Oncology, 2008
  • UCLA Clinical and Translational Science Institute Scholars Program, 2008
  • Cedars-Sinai Medical Staff Leadership Development Program, 2008
  • Faculty Golden Apple Teaching Award, 2007
  • Career Development Award, Pacific Ovarian Cancer Research Consortium, 2007
  • Berlex Scholar Award in Basic Science Research, 2007
  • Alumni Association Award for Outstanding Service to Columbia P&S, 1998
  • Alpha Omega Alpha Medical Honor Society, 1998

Show moreShow less

  • Walsh CS, Karlan BY. Contemporary progress in ovarian cancer screening. Curr Oncol Rep. 2007;9(6):485-493.
  • Walsh CS. Two decades beyond BRCA1/2: homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy. Gynecol Oncol. 2015;137(2):343-350.
  • Diaz ES, Walts AE, Karlan BY, Walsh CS. Venous thromboembolism during primary treatment of ovarian clear cell carcinoma is associated with decreased survival. Gynecol Oncol. 2013;131(3):541-545.
  • Walsh C, Holschneider C, Hoang Y, Tieu K, Karlan B, Cass I. Coexisting ovarian malignancy in young women with endometrial cancer. Obstetrics and Gynecology. 2005;106(4):693-699.
  • Walsh CS, Miller CW, Karlan BY, Koeffler HP. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol Oncol. 2006;104(3):660-664.
  • Walsh CS, Ogawa S, Karahashi H, Scoles DR, Pavelka JC, Tran H, Miller CW, Kawamata N, Ginther C, Dering J, et al. ERCC5 is a novel biomarker of ovarian cancer prognosis. J Clin Oncol. 2008;26(18):2952-2958.

Show moreShow less


Make an Appointment




Available 24 Hours A Day


Many of the physicians who have medical staff privileges to practice medicine at Cedars-Sinai Medical Center are independent physicians, and not employees or agents of the hospital. These independent physicians bill separately for their services. You should contact your physician to determine their status and billing practices.

Send Email to Christine S. Walsh, MD